By Peggy Peck, Executive Editor, MedPage TodayPublished: August 29, 2010
STOCKHOLM -- Intracoronary bone marrow cell transplantation extended survival in patients with chronic heart failure due to ischemic cardiomyopathy -- that was the good news. The bad news was that the finding was not "new" at all -- it had already been published.
Late today the European Society of Cardiology said it would sanction the researcher who reported the stem cell study by barring him from presenting research at ESC congresses for two years.
The ESC guidelines for Hot Line trials specifically state that the information submitted should be new, unpublished data. Yet, the STAR trial was accepted for presentation as a Hot Line trial at the ESC annual meeting here./.../
No comments:
Post a Comment